Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127


Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries.

Iorio A, Stonebraker JS, Chambost H, Makris M, Coffin D, Herr C, Germini F; Data and Demographics Committee of the World Federation of Hemophilia.

Ann Intern Med. 2019 Sep 10. doi: 10.7326/M19-1208. [Epub ahead of print]


Congenital factor XIII deficiency: comprehensive overview of the FranceCoag cohort.

Bouttefroy S, Meunier S, Milien V, Boucekine M, Chamouni P, Desprez D, Harroche A, Hochart A, Thiercelin-Legrand MF, Wibaut B, Chambost H, Rugeri L; CoDeC study group.

Br J Haematol. 2019 Aug 14. doi: 10.1111/bjh.16133. [Epub ahead of print]


Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra® ): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP).

Susen S, Gruel Y, Godier A, Harroche A, Chambost H, Lasne D, Rauch A, Roullet S, Fontana P, Goudemand J, de Maistre E, Chamouard V, Wibaut B, Albaladejo P, Négrier C.

Haemophilia. 2019 Sep;25(5):731-737. doi: 10.1111/hae.13817. Epub 2019 Jul 11. Review.


Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A.

van den Berg HM, Fischer K, Carcao M, Chambost H, Kenet G, Kurnik K, Königs C, Male C, Santagostino E, Ljung R; PedNet Study Group.

Blood. 2019 Jul 18;134(3):317-320. doi: 10.1182/blood.2019000658. Epub 2019 Jun 11. No abstract available.


Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies.

Volkers P, Hanschmann KM, Calvez T, Chambost H, Collins PW, Demiguel V, Hart DP, Hay CRM, Goudemand J, Ljung R, Palmer BP, Santagostino E, van Hardeveld EM, van den Berg M, Keller-Stanislawski B.

Haemophilia. 2019 May;25(3):398-407. doi: 10.1111/hae.13747. Epub 2019 May 7.


Binding of Coagulation Factor XIII Zymogen to Activated Platelet Subpopulations: Roles of Integrin αIIbβ3 and Fibrinogen.

Kotova YN, Podoplelova NA, Obydennyy SI, Kostanova EA, Ryabykh AA, Demyanova AS, Biriukova MI, Rosenfeld MA, Sokolov AV, Chambost H, Kumskova MA, Ataullakhanov FI, Alessi MC, Panteleev MA.

Thromb Haemost. 2019 Jun;119(6):906-915. doi: 10.1055/s-0039-1683912. Epub 2019 Apr 1.


Lipodystrophy-like features after total body irradiation among survivors of childhood acute leukemia.

Visentin S, Michel G, Oudin C, Cousin B, Gaborit B, Abdesselam I, Maraninchi M, Nowicki M, Valero R, Guye M, Bernard M, Auquier P, Chambost H, Alessi MC, Beliard S.

Endocr Connect. 2019 Mar 1. pii: EC-18-0497.R2. doi: 10.1530/EC-18-0497. [Epub ahead of print]


Mode of delivery in hemophilia: vaginal delivery and Cesarean section carry similar risks for intracranial hemorrhages and other major bleeds.

Andersson NG, Chalmers EA, Kenet G, Ljung R, Mäkipernaa A, Chambost H; PedNet Haemophilia Research Foundation.

Haematologica. 2019 Oct;104(10):2100-2106. doi: 10.3324/haematol.2018.209619. Epub 2019 Feb 21.


Tissue factor pathway inhibitor is the main determinant of thrombin generation in haemophilic patients.

Chelle P, Montmartin A, Damien P, Piot M, Cournil M, Lienhart A, Genre-Volot F, Chambost H, Morin C, Tardy-Poncet B.

Haemophilia. 2019 Mar;25(2):343-348. doi: 10.1111/hae.13679. Epub 2019 Jan 28.


Neurological Involvement in Childhood Evans Syndrome.

Pincez T, Neven B, Le Pointe HD, Varlet P, Fernandes H, Gareton A, Leverger G, Leblanc T, Chambost H, Michel G, Pasquet M, Millot F, Hermine O, Mathian A, Hully M, Zephir H, Hamidou M, Durand JM, Perel Y, Landman-Parker J, Rieux-Laucat F, Aladjidi N.

J Clin Immunol. 2019 Feb;39(2):171-181. doi: 10.1007/s10875-019-0594-3. Epub 2019 Jan 22.


[Clinical management of patients with hemophilia A in nephrology: Diagnostic and therapeutic challenges illustrated by the cases of 2 patients].

Fedi M, Falaise C, Lanot A, Von Kotze C, Robert T, Piétri L, Henri P, Delmotte N, Botta D, Verhelst D, Chambost H, Brunet P, Jourde-Chiche N.

Nephrol Ther. 2019 Apr;15(2):77-81. doi: 10.1016/j.nephro.2018.10.002. Epub 2019 Jan 16. French.


FranceCoag: a 22-year prospective follow-up of the national French cohort of patients with inherited bleeding disorders.

Doncarli A, Demiguel V, Guseva Canu I, Goulet V, Bayart S, Calvez T, Castet S, Dalibard V, Demay Y, Frotscher B, Goudemand J, Lambert T, Milien V, Oudot C, Sannié T, Chambost H; FranceCoag Network.

Eur J Epidemiol. 2019 May;34(5):521-532. doi: 10.1007/s10654-018-0468-7. Epub 2018 Dec 5.


Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): study protocol for a multicentric French national observational cross-sectional study.

Resseguier N, Rosso-Delsemme N, Beltran Anzola A, Baumstarck K, Milien V, Ardillon L, Bayart S, Berger C, Bertrand MA, Biron-Andreani C, Borel-Derlon A, Castet S, Chamouni P, Claeyssens Donadel S, De Raucourt E, Desprez D, Falaise C, Frotscher B, Gay V, Goudemand J, Gruel Y, Guillet B, Harroche A, Hassoun A, Huguenin Y, Lambert T, Lebreton A, Lienhart A, Martin M, Meunier S, Monpoux F, Mourey G, Negrier C, Nguyen P, Nyombe P, Oudot C, Pan-Petesch B, Polack B, Rafowicz A, Rauch A, Rivaud D, Schneider P, Spiegel A, Stoven C, Tardy B, Trossaërt M, Valentin JB, Vanderbecken S, Volot F, Voyer-Ebrard A, Wibaut B, Leroy T, Sannie T, Chambost H, Auquier P.

BMJ Open. 2018 Jul 25;8(7):e022409. doi: 10.1136/bmjopen-2018-022409.


Long-term management of leukocyte adhesion deficiency type III without hematopoietic stem cell transplantation.

Saultier P, Szepetowski S, Canault M, Falaise C, Poggi M, Suchon P, Barlogis V, Michel G, Loyau S, Jandrot-Perrus M, Bordet JC, Alessi MC, Chambost H.

Haematologica. 2018 Jun;103(6):e264-e267. doi: 10.3324/haematol.2017.186304. Epub 2018 Feb 22. Review. No abstract available.


Real-World Early Treatment with Room Temperature-Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses.

Demartis F, Batorova A, Chambost H, Eshghi P, Karimi M, Kavakli K, El Fegoun SB, Cepo K, Vestergaard LS, Benson G.

TH Open. 2017 Dec 8;1(2):e130-e138. doi: 10.1055/s-0037-1608943. eCollection 2017 Jul.


Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors.

Mancuso ME, Fischer K, Santagostino E, Oldenburg J, Platokouki H, Königs C, Escuriola-Ettingshausen C, Rivard GE, Cid AR, Carcao M, Ljung R, Petrini P, Altisent C, Kenet G, Liesner R, Kurnik K, Auerswald G, Chambost H, Mäkipernaa A, Molinari AC, Williams M, van den Berg HM; European Pediatric Network for Haemophilia Management (PedNet) the REMAIN (REal life MAnagement of children with INhibitors) Study Group.

Thromb Haemost. 2017 Dec;117(12):2274-2282. doi: 10.1160/TH17-01-0059. Epub 2017 Dec 6.


Plasma 7-Hydroxymethotrexate Levels Versus Methotrexate to Predict Delayed Elimination in Children Receiving High-Dose Methotrexate.

Fabresse N, Devictor B, Pissier C, Chambost H, Lacarelle B, Michel G, Solas C.

Ther Drug Monit. 2018 Feb;40(1):76-83. doi: 10.1097/FTD.0000000000000445.


Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.

Calvez T, Chambost H, d'Oiron R, Dalibard V, Demiguel V, Doncarli A, Gruel Y, Huguenin Y, Lutz P, Rothschild C, Vinciguerra C, Goudemand J; for FranceCoag Collaborators.

Haematologica. 2018 Jan;103(1):179-189. doi: 10.3324/haematol.2017.174706. Epub 2017 Oct 12.


Hematopoietic stem cell transplantation for the treatment of leukocyte adhesion deficiency type III.

Saultier P, Alessi MC, Michel G, Chambost H.

Pediatr Neonatol. 2017 Dec;58(6):560-561. doi: 10.1016/j.pedneo.2017.07.006. Epub 2017 Jul 24. No abstract available.


Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study.

Liesner RJ, Abashidze M, Aleinikova O, Altisent C, Belletrutti MJ, Borel-Derlon A, Carcao M, Chambost H, Chan AKC, Dubey L, Ducore J, Fouzia NA, Gattens M, Gruel Y, Guillet B, Kavardakova N, El Khorassani M, Klukowska A, Lambert T, Lohade S, Sigaud M, Turea V, Wu JKM, Vdovin V, Pavlova A, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ.

Haemophilia. 2018 Mar;24(2):211-220. doi: 10.1111/hae.13320. Epub 2017 Aug 16.


Molecular cytogenetic characterization of five F8 complex rearrangements: utility for haemophilia A genetic counselling.

Jourdy Y, Chatron N, Fretigny M, Carage ML, Chambost H, Claeyssens-Donadel S, Roussel-Robert V, Negrier C, Sanlaville D, Vinciguerra C.

Haemophilia. 2017 Jul;23(4):e316-e323. doi: 10.1111/hae.13218. Epub 2017 May 5.


Benefits of rituximab as a second-line treatment for autoimmune haemolytic anaemia in children: a prospective French cohort study.

Ducassou S, Leverger G, Fernandes H, Chambost H, Bertrand Y, Armari-Alla C, Nelken B, Monpoux F, Guitton C, Leblanc T, Fisher A, Lejars O, Jeziorski E, Fouissac F, Lutz P, Pasquet M, Pellier I, Piguet C, Vic P, Bayart S, Marie-Cardine A, Michel M, Perel Y, Aladjidi N.

Br J Haematol. 2017 Jun;177(5):751-758. doi: 10.1111/bjh.14627. Epub 2017 Apr 26.


Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study.

Kavakli K, Demartis F, Karimi M, Eshghi P, Neme D, Chambost H, Sommer L, Zak M, Benson G.

Haemophilia. 2017 Jul;23(4):575-582. doi: 10.1111/hae.13227. Epub 2017 Apr 24.


The second Team Haemophilia Education Meeting, 2016, Frankfurt, Germany.

Berntorp E, Dargaud Y, Hart D, Lobet S, Mancuso ME, d'Oiron R, Perry D, Pollard D, van den Berg M, Blatný J, Chambost H, Doria AS, Holme PA, Kaczmarek R, Mantovani L, McLaughlin P, Nanayakkara L, Petrini P, Sannié T, Laane E, Maia R, Dettoraki A, Farrell A, Halimeh S, Raza S, Taylor S.

Eur J Haematol. 2017 Jan;98 Suppl 85:1-15. doi: 10.1111/ejh.12828.


Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25).

Meunier S, d'oiron R, Chambost H, Dolimier E, Guillet B; ORTHem 15-25 Study Group.

Thromb Res. 2017 Mar;151:17-22. doi: 10.1016/j.thromres.2016.12.023. Epub 2016 Dec 28.


α1 -antitrypsin Pittsburgh and plasmin-mediated proteolysis.

Henneuse A, Suchon P, Chambost H, Morange PE, Frere C, Alessi MC.

J Thromb Haemost. 2016 Oct;14(10):2023-2026. doi: 10.1111/jth.13426. Epub 2016 Sep 2.


Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.

Joly BS, Stepanian A, Leblanc T, Hajage D, Chambost H, Harambat J, Fouyssac F, Guigonis V, Leverger G, Ulinski T, Kwon T, Loirat C, Coppo P, Veyradier A; French Reference Center for Thrombotic Microangiopathies.

Lancet Haematol. 2016 Nov;3(11):e537-e546. doi: 10.1016/S2352-3026(16)30125-9. Epub 2016 Oct 3.


Prevalence and risk factors of iron overload after hematopoietic stem cell transplantation for childhood acute leukemia: a LEA study.

Sirvent A, Auquier P, Oudin C, Bertrand Y, Bohrer S, Chastagner P, Poirée M, Kanold J, Thouvenin S, Perel Y, Plantaz D, Tabone MD, Yakouben K, Gandemer V, Lutz P, Sirvent N, Vercasson C, Berbis J, Chambost H, Leverger G, Baruchel A, Michel G.

Bone Marrow Transplant. 2017 Jan;52(1):80-87. doi: 10.1038/bmt.2016.205. Epub 2016 Sep 5.


Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial.

Kenet G, Chambost H, Male C, Lambert T, Halimeh S, Chernova T, Mancuso ME, Curtin J, Voigt C, Li Y, Jacobs I, Santagostino E; PROLONG-9FP Investigator Study Group.

Thromb Haemost. 2016 Sep 27;116(4):659-68. doi: 10.1160/TH16-03-0179. Epub 2016 Sep 1.


The Impact of Donor Type on Long-Term Health Status and Quality of Life after Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Acute Leukemia: A Leucémie de l'Enfant et de L'Adolescent Study.

Visentin S, Auquier P, Bertrand Y, Baruchel A, Tabone MD, Pochon C, Jubert C, Poirée M, Gandemer V, Sirvent A, Bonneau J, Paillard C, Freycon C, Kanold J, Villes V, Berbis J, Oudin C, Galambrun C, Pellier I, Plat G, Chambost H, Leverger G, Dalle JH, Michel G.

Biol Blood Marrow Transplant. 2016 Nov;22(11):2003-2010. doi: 10.1016/j.bbmt.2016.08.004. Epub 2016 Aug 10.


Metabolic syndrome in long-term survivors of childhood acute leukemia treated without hematopoietic stem cell transplantation: an L.E.A. study.

Saultier P, Auquier P, Bertrand Y, Vercasson C, Oudin C, Contet A, Plantaz D, Poirée M, Ducassou S, Kanold J, Tabone MD, Dalle JH, Lutz P, Gandemer V, Sirvent N, Thouvenin S, Berbis J, Chambost H, Baruchel A, Leverger G, Michel G.

Haematologica. 2016 Dec;101(12):1603-1610. Epub 2016 Aug 11.


Hysteresis-like binding of coagulation factors X/Xa to procoagulant activated platelets and phospholipids results from multistep association and membrane-dependent multimerization.

Podoplelova NA, Sveshnikova AN, Kurasawa JH, Sarafanov AG, Chambost H, Vasil'ev SA, Demina IA, Ataullakhanov FI, Alessi MC, Panteleev MA.

Biochim Biophys Acta. 2016 Jun;1858(6):1216-27. doi: 10.1016/j.bbamem.2016.02.008. Epub 2016 Feb 10. Review.


Evans Syndrome in Children: Long-Term Outcome in a Prospective French National Observational Cohort.

Aladjidi N, Fernandes H, Leblanc T, Vareliette A, Rieux-Laucat F, Bertrand Y, Chambost H, Pasquet M, Mazingue F, Guitton C, Pellier I, Roqueplan-Bellmann F, Armari-Alla C, Thomas C, Marie-Cardine A, Lejars O, Fouyssac F, Bayart S, Lutz P, Piguet C, Jeziorski E, Rohrlich P, Lemoine P, Bodet D, Paillard C, Couillault G, Millot F, Fischer A, Pérel Y, Leverger G.

Front Pediatr. 2015 Sep 29;3:79. doi: 10.3389/fped.2015.00079. eCollection 2015.


Response: Confounding by indication is unlikely to explain the higher inhibitor incidence in boys treated with a recombinant FVIII product.

Calvez T, Chambost H, Lutz P, Rothschild C, Goudemand J.

Blood. 2015 Jun 11;125(24):3817-9. doi: 10.1182/blood-2015-02-622167. No abstract available.


Accidental poisoning with 6-MP in a sibling of pediatric patient treated with maintenance chemotherapy.

Fernandez A, Gervoise-Boyer MJ, Chambost H, Coze C, Andre N.

J Pediatr Hematol Oncol. 2015 May;37(4):331-2. doi: 10.1097/MPH.0000000000000328. No abstract available.


EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France.

Polack B, Calvez T, Chambost H, Rothschild C, Goudemand J, Claeyssens S, Borel-Derlon A, Bardoulat I, Maurel F, Woronoff-Lemsi MC; EQOFIX Study Group.

Transfusion. 2015 Jul;55(7):1787-97. doi: 10.1111/trf.13016. Epub 2015 Feb 5.


Late cardiomyopathy in childhood acute myeloid leukemia survivors: a study from the L.E.A. program.

Barlogis V, Auquier P, Bertrand Y, Chastagner P, Plantaz D, Poiree M, Kanold J, Berbis J, Oudin C, Vercasson C, Allouche M, Tabone MD, Thouvenin-Doulet S, Saumet L, Chambost H, Baruchel A, Leverger G, Michel G.

Haematologica. 2015 May;100(5):e186-9. doi: 10.3324/haematol.2014.116574. Epub 2015 Jan 23. No abstract available.


Full but impaired activation of innate immunity effectors and virus-specific T cells during CMV and EBV disease following cord blood transplantation.

Farnault L, Gertner-Dardenne J, Gondois-Rey F, Michel G, Chambost H, Hirsch I, Olive D.

Bone Marrow Transplant. 2015 Mar;50(3):459-62. doi: 10.1038/bmt.2014.275. Epub 2015 Jan 19. No abstract available.


[Scurvy, an old disease still in the news: two case reports].

Pailhous S, Lamoureux S, Caietta E, Bosdure E, Chambost H, Chabrol B, Bresson V.

Arch Pediatr. 2015 Jan;22(1):63-5. doi: 10.1016/j.arcped.2014.10.003. Epub 2014 Nov 20. French.


Quality of life in minor siblings of childhood leukemia survivors, long-term after diagnosis: A LEA study (for Leucemies de l'Enfant et de l'Adolescent--childhood and adolescent leukemia).

Berbis J, Oudin C, Alessandrini M, Vercasson C, Barlogis V, Chambost H, Michel G, Auquier P.

Psychooncology. 2015 Jun;24(6):661-8. doi: 10.1002/pon.3709. Epub 2014 Oct 28.


[Platelet transfusion and immunization anti-Rh1: implication for immunoprophylaxis].

Chambost H.

Transfus Clin Biol. 2014 Nov;21(4-5):210-5. doi: 10.1016/j.tracli.2014.08.137. Epub 2014 Oct 2. French.


Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A.

Calvez T, Chambost H, Claeyssens-Donadel S, d'Oiron R, Goulet V, Guillet B, Héritier V, Milien V, Rothschild C, Roussel-Robert V, Vinciguerra C, Goudemand J; FranceCoag Network.

Blood. 2014 Nov 27;124(23):3398-408. doi: 10.1182/blood-2014-07-586347. Epub 2014 Sep 24.


Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.

Powell JS, Apte S, Chambost H, Hermans C, Jackson S, Josephson NC, Mahlangu JN, Ozelo MC, Peerlinck K, Pasi J, Perry D, Ragni MV, Wang X, Jiang H, Li S, Cristiano LM, Innes A, Nugent K, Brennan A, Luk A, Allen G, Pierce GF, Robinson B.

Br J Haematol. 2015 Jan;168(1):124-34. doi: 10.1111/bjh.13112. Epub 2014 Sep 11.


Health status and quality of life of long-term survivors of childhood acute leukemia: the impact of central nervous system irradiation.

Benadiba J, Michel G, Auquier P, Chastagner P, Kanold J, Poirée M, Plantaz D, Padovani L, Berbis J, Barlogis V, Contet A, Chambost H, Sirvent N.

J Pediatr Hematol Oncol. 2015 Mar;37(2):109-16. doi: 10.1097/MPH.0000000000000209.


Peripheral blood cells chimerism after unrelated cord blood transplantation in children: kinetics, predictive factors and impact on post-transplant outcome.

Elkaim E, Picard C, Galambrun C, Barlogis V, Loundou A, Curtillet C, Oudin C, Thuret I, Chambost H, Michel G.

Br J Haematol. 2014 Aug;166(4):557-65. doi: 10.1111/bjh.12918. Epub 2014 Apr 29.


Health status of childhood leukemia survivors who received hematopoietic cell transplantation after BU or TBI: an LEA study.

Bernard F, Auquier P, Herrmann I, Contet A, Poiree M, Demeocq F, Plantaz D, Galambrun C, Barlogis V, Berbis J, Garnier F, Sirvent N, Kanold J, Chastagner P, Chambost H, Michel G.

Bone Marrow Transplant. 2014 May;49(5):709-16. doi: 10.1038/bmt.2014.3. Epub 2014 Feb 17.


Prevalence and risk factors of cataract after chemotherapy with or without central nervous system irradiation for childhood acute lymphoblastic leukaemia: an LEA study.

Alloin AL, Barlogis V, Auquier P, Contet A, Poiree M, Demeocq F, Herrmann I, Villes V, Bertrand Y, Plantaz D, Kanold J, Chastagner P, Chambost H, Sirvent N, Michel G.

Br J Haematol. 2014 Jan;164(1):94-100. doi: 10.1111/bjh.12598. Epub 2013 Oct 14.


[Infantile visceral leishmaniasis, an etiology of easily curable hemophagocytic lymphohistiocytosis syndrome].

Visentin S, Baudesson de Chanville A, Loosveld M, Chambost H, Barlogis V.

Arch Pediatr. 2013 Nov;20(11):1225-9. doi: 10.1016/j.arcped.2013.08.003. Epub 2013 Sep 26. French.


Procoagulant platelets form an α-granule protein-covered "cap" on their surface that promotes their attachment to aggregates.

Abaeva AA, Canault M, Kotova YN, Obydennyy SI, Yakimenko AO, Podoplelova NA, Kolyadko VN, Chambost H, Mazurov AV, Ataullakhanov FI, Nurden AT, Alessi MC, Panteleev MA.

J Biol Chem. 2013 Oct 11;288(41):29621-32. doi: 10.1074/jbc.M113.474163. Epub 2013 Aug 30.


Cancer detection and management in patients with haemophilia: a retrospective European multicentre study.

Biron-Andreani C, de Moerloose P, D'oiron R, Chambost H, Schved JF, Hermans C.

Haemophilia. 2014 Jan;20(1):78-82. doi: 10.1111/hae.12250. Epub 2013 Aug 6.


Supplemental Content

Loading ...
Support Center